Works by Takahashi, Koichi


Results: 273
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00915-6
    By:
    • Hammond, Danielle;
    • Loghavi, Sanam;
    • Wang, Sa A.;
    • Konopleva, Marina Y.;
    • Kadia, Tapan M.;
    • Daver, Naval G.;
    • Ohanian, Maro;
    • Issa, Ghayas C.;
    • Alvarado, Yesid;
    • Short, Nicholas J.;
    • Sasaki, Koji;
    • Pemmaraju, Naveen;
    • Montalban-Bravo, Guillermo;
    • Lachowiez, Curtis A.;
    • Maiti, Abhishek;
    • Garcia-Manero, Guillermo;
    • Jabbour, Elias J.;
    • Borthakur, Gautam;
    • Ravandi, Farhad;
    • Takahashi, Koichi
    Publication type:
    Article
    31

    Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00826-6
    By:
    • Fiskus, Warren;
    • Mill, Christopher P.;
    • Birdwell, Christine;
    • Davis, John A.;
    • Das, Kaberi;
    • Boettcher, Steffen;
    • Kadia, Tapan M.;
    • DiNardo, Courtney D.;
    • Takahashi, Koichi;
    • Loghavi, Sanam;
    • Soth, Michael J.;
    • Heffernan, Tim;
    • McGeehan, Gerard M.;
    • Ruan, Xinjia;
    • Su, Xiaoping;
    • Vakoc, Christopher R.;
    • Daver, Naval;
    • Bhalla, Kapil N.
    Publication type:
    Article
    32

    Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00826-6
    By:
    • Fiskus, Warren;
    • Mill, Christopher P.;
    • Birdwell, Christine;
    • Davis, John A.;
    • Das, Kaberi;
    • Boettcher, Steffen;
    • Kadia, Tapan M.;
    • DiNardo, Courtney D.;
    • Takahashi, Koichi;
    • Loghavi, Sanam;
    • Soth, Michael J.;
    • Heffernan, Tim;
    • McGeehan, Gerard M.;
    • Ruan, Xinjia;
    • Su, Xiaoping;
    • Vakoc, Christopher R.;
    • Daver, Naval;
    • Bhalla, Kapil N.
    Publication type:
    Article
    33

    Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 5, p. 1, doi. 10.1038/s41408-022-00670-0
    By:
    • Yilmaz, Musa;
    • Kantarjian, Hagop;
    • Short, Nicholas J.;
    • Reville, Patrick;
    • Konopleva, Marina;
    • Kadia, Tapan;
    • DiNardo, Courtney;
    • Borthakur, Gautam;
    • Pemmaraju, Naveen;
    • Maiti, Abhishek;
    • Jabbour, Elias;
    • Jain, Nitin;
    • Issa, Ghayas;
    • Takahashi, Koichi;
    • Sasaki, Koji;
    • Ohanian, Maro;
    • Pierce, Sherry;
    • Tang, Guillin;
    • Loghavi, Sanam;
    • Patel, Keyur
    Publication type:
    Article
    34

    Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00604-2
    By:
    • Venugopal, Sangeetha;
    • Takahashi, Koichi;
    • Daver, Naval;
    • Maiti, Abhishek;
    • Borthakur, Gautam;
    • Loghavi, Sanam;
    • Short, Nicholas. J.;
    • Ohanian, Maro;
    • Masarova, Lucia;
    • Issa, Ghayas;
    • Wang, Xuemei;
    • Carlos, Bueso-Ramos;
    • Yilmaz, Musa;
    • Kadia, Tapan;
    • Andreeff, Michael;
    • Ravandi, Farhad;
    • Konopleva, Marina;
    • Kantarjian, Hagop M.;
    • DiNardo, Courtney D.
    Publication type:
    Article
    35
    36

    Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00487-3
    By:
    • Fiskus, Warren;
    • Mill, Christopher P.;
    • Nabet, Behnam;
    • Perera, Dimuthu;
    • Birdwell, Christine;
    • Manshouri, Taghi;
    • Lara, Bernardo;
    • Kadia, Tapan M.;
    • DiNardo, Courtney;
    • Takahashi, Koichi;
    • Daver, Naval;
    • Bose, Prithviraj;
    • Masarova, Lucia;
    • Pemmaraju, Naveen;
    • Kornblau, Steven;
    • Borthakur, Gautam;
    • Montalban-Bravo, Guillermo;
    • Manero, Guillermo Garcia;
    • Sharma, Sunil;
    • Stubbs, Matthew
    Publication type:
    Article
    37
    38

    Nrf2 regulates haematopoietic stem cell function.

    Published in:
    Nature Cell Biology, 2013, v. 15, n. 3, p. 309, doi. 10.1038/ncb2699
    By:
    • Tsai, Jennifer J.;
    • Dudakov, Jarrod A.;
    • Takahashi, Koichi;
    • Shieh, Jae-Hung;
    • Velardi, Enrico;
    • Holland, Amanda M.;
    • Singer, Natalie V.;
    • West, Mallory L.;
    • Smith, Odette M.;
    • Young, Lauren F.;
    • Shono, Yusuke;
    • Ghosh, Arnab;
    • Hanash, Alan M.;
    • Tran, Hien T.;
    • Moore, Malcolm A. S.;
    • van den Brink, Marcel R. M.
    Publication type:
    Article
    39

    Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.

    Published in:
    Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-04924-z
    By:
    • Koichi Takahashi;
    • Feng Wang;
    • Morita, Kiyomi;
    • Yuanqing Yan;
    • Hu, Peter;
    • Pei Zhao;
    • Zhar, Abdallah Abou;
    • Chang Jiun Wu;
    • Gumbs, Curtis;
    • Little, Latasha;
    • Tippen, Samantha;
    • Thornton, Rebecca;
    • Coyle, Marcus;
    • Mendoza, Marisela;
    • Thompson, Erika;
    • Jianhua Zhang;
    • DiNardo, Courtney D.;
    • Jain, Nitin;
    • Ravandi, Farhad;
    • Cortes, Jorge E.
    Publication type:
    Article
    40

    TP53 Y220C mutations in patients with myeloid malignancies.

    Published in:
    2024
    By:
    • Gener-Ricos, Georgina;
    • Bewersdorf, Jan P.;
    • Loghavi, Sanam;
    • Bataller, Alex;
    • Goldberg, Aaron D.;
    • Sasaki, Koji;
    • Famulare, Christopher;
    • Takahashi, Koichi;
    • Issa, Ghayas C.;
    • Borthakur, Gautam;
    • Kadia, Tapan M.;
    • Short, Nicholas J.;
    • Senapati, Jayastu;
    • Carter, Bing Z.;
    • Patel, Keyur P.;
    • Kantarjian, Hagop;
    • Andreeff, Michael;
    • Stein, Eytan M.;
    • DiNardo, Courtney D.
    Publication type:
    Letter to the Editor
    41

    A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 9, p. 2161, doi. 10.1080/10428194.2022.2062345
    By:
    • Short, Nicholas J.;
    • Borthakur, Gautam;
    • Pemmaraju, Naveen;
    • Dinardo, Courtney D.;
    • Kadia, Tapan M.;
    • Jabbour, Elias;
    • Konopleva, Marina;
    • Macaron, Walid;
    • Ning, Jing;
    • Ma, Junsheng;
    • Pierce, Sherry;
    • Alvarado, Yesid;
    • Sasaki, Koji;
    • Takahashi, Koichi;
    • Estrov, Zeev;
    • Masarova, Lucia;
    • Issa, Ghayas C.;
    • Montalban-Bravo, Guillermo;
    • Andreeff, Michael;
    • Burger, Jan A.
    Publication type:
    Article
    42
    43

    MYC protein expression is an important prognostic factor in acute myeloid leukemia.

    Published in:
    Leukemia & Lymphoma, 2019, v. 60, n. 1, p. 37, doi. 10.1080/10428194.2018.1464158
    By:
    • Ohanian, Maro;
    • Rozovski, Uri;
    • Kanagal-Shamanna, Rashmi;
    • Abruzzo, Lynne V.;
    • Loghavi, Sanam;
    • Kadia, Tapan;
    • Futreal, Andrew;
    • Bhalla, Kapil;
    • Zuo, Zhuang;
    • Huh, Yang O.;
    • Post, Sean M.;
    • Ruvolo, Peter;
    • Garcia-Manero, Guillermo;
    • Andreeff, Michael;
    • Kornblau, Steven;
    • Borthakur, Gautam;
    • Hu, Peter;
    • Medeiros, L. Jeffrey;
    • Takahashi, Koichi;
    • Hornbaker, Marisa J.
    Publication type:
    Article
    44

    Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 9, p. 2238, doi. 10.1080/10428194.2017.1422864
    By:
    • Boddu, Prajwal;
    • Kantarjian, Hagop;
    • Ravandi, Farhad;
    • Garcia-Manero, Guillermo;
    • Borthakur, Gautam;
    • Andreeff, Michael;
    • Jabbour, Elias J.;
    • Benton, Christopher B.;
    • DiNardo, Courtney D.;
    • Konopleva, Marina;
    • Daver, Naval;
    • Patel, Keyur;
    • Takahashi, Koichi;
    • Kanagal-Shamanna, Rashmi;
    • Cortes, Jorge;
    • Kadia, Tapan
    Publication type:
    Article
    45
    46
    47
    48

    Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.

    Published in:
    American Journal of Hematology, 2024, v. 99, n. 7, p. 1434, doi. 10.1002/ajh.27333
    By:
    • Abuasab, Tareq;
    • Borthakur, Gautam;
    • Kanagal‐Shamanna, Rashmi;
    • Masarova, Lucia;
    • Patel, Keyur;
    • Takahashi, Koichi;
    • Bose, Prithviraj;
    • Villarreal, John;
    • Pierce, Sherry;
    • Kadia, Tapan;
    • Garcia‐Manero, Guillermo;
    • Short, Nicholas J.;
    • DiNardo, Courtney;
    • Daver, Naval;
    • Ravandi, Farhad;
    • Kantarjian, Hagop;
    • Verstovsek, Srdan;
    • Yilmaz, Musa
    Publication type:
    Article
    49

    Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 12, p. 1599, doi. 10.1002/ajh.26731
    By:
    • Rivera, Daniel;
    • Kim, Kunhwa;
    • Kanagal‐Shamanna, Rashmi;
    • Borthakur, Gautam;
    • Montalban‐Bravo, Guillermo;
    • Daver, Naval;
    • Dinardo, Courtney;
    • Short, Nicholas J.;
    • Yilmaz, Musa;
    • Pemmaraju, Naveen;
    • Takahashi, Koichi;
    • Jabbour, Elias J.;
    • Pierce, Sherry;
    • Konopleva, Marina;
    • Bhalla, Kapil;
    • Garcia‐Manero, Guillermo;
    • Ravandi, Farhad;
    • Kantarjian, Hagop;
    • Kadia, Tapan M.
    Publication type:
    Article
    50

    Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 11, p. 1427, doi. 10.1002/ajh.26700
    By:
    • Borthakur, Gautam;
    • Ravandi, Farhad;
    • Patel, Keyur;
    • Wang, Xuemei;
    • Kadia, Tapan;
    • DiNardo, Courtney;
    • Garcia‐Manero, Guillermo;
    • Pemmaraju, Naveen;
    • Jabbour, Elias J.;
    • Takahashi, Koichi;
    • Ohanian, Maro;
    • Daver, Naval;
    • Alvarado, Yesid;
    • Brandt, Mark;
    • Pierce, Sherry;
    • Kantarjian, Hagop
    Publication type:
    Article